Table 1.
Peer-reviewed publications included in the scoping study
| Primary authors | Ethical issues emphasized | Setting | Method* |
|---|---|---|---|
| Bärnighausen T, Salomon JA, Sangrujee N: HIV Treatment as Prevention: Issues in Economic Evaluation.PLoS Med 2012, 9:e1001263. |
A, B, C |
Worldwide |
Commentary |
| Bärnighausen T, Tanser F, Dabis F, Newell M-L: Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa.Current Opinion in HIV and AIDS 2012, 7: 140–150. |
C |
Sub-Saharan Africa |
Rapid Review |
| Barr D, Amon JJ, Clayton M: Articulating a rights-based approach to HIV treatment and prevention interventions. Current HIV research 2011, 9: 396–404. |
A, B |
Worldwide |
Commentary |
| Chan R: Biomedical Strategies for Human Immunodeficiency Virus (HIV) Prevention? A New Paradigm.Ann Acad Med Singapore 2012, 41: 595–601. |
A, B, C |
Worldwide |
Review |
| Chang LW, Serwadda D, Quinn TC, Wawer MJ: Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects.Lancet Infect Dis 2013, 13:65–76. |
C |
Sub-Saharan Africa |
Review |
| Chen Y: Treatment-Related Optimistic Beliefs and Risk of HIV Transmission: A Review of Recent Findings (2009–2012) in an Era of Treatment as Prevention.Curr HIV/AIDS Rep 2012, 10: 79–88. |
C |
Worldwide |
Review |
| Cohen T, Corbett EL: Test and treat in HIV: success could depend on rapid detection.The Lancet 2011, 378: 204–206. |
A, B, C |
Sub-Saharan Africa |
Commentary |
| Dawson L: The Devil in the Details: Thorough Assessment of Evidence and Ethics Is Needed in Evaluating New HIV Prevention Methods.Am J Bioethics 2012, 12: 33–34. |
A, C |
Worldwide |
Commentary |
| Dennin RH, Lafrenz M, Sinn A, Li L: Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights.J Zhejiang U 2011, 12: 591–610. |
A |
Worldwide |
Commentary |
| Forsyth AD, Valdiserri RO: Reaping the prevention benefits of highly active antiretroviral treatment.Current Opinion in HIV and AIDS 2012, 7: 111–116. |
A, B, C |
Worldwide |
Commentary |
| Garnett GP, Baggaley RF: Treating our way out of the HIV pandemic: could we, would we, should we?The Lancet 2009, 373: 9–11. |
A, C |
Worldwide |
Commentary |
| Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sonnerborg A, Nachega JB: Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs.J Infect Dis 2013, 207: S101–S106. |
C |
International |
Commentary |
| Haire BG: Because we can: clashes of perspective over researcher obligation in the failed PrEP trials.Dev world bioethics 2011,11: 63–74. |
A, B, C |
Worldwide |
Commentary |
| Haire BG, Kaldor J, Jordens CFC: How good is “good enough”? The case for varying standards of evidence according to need for new interventions in HIV prevention.Am J Bioethics 2012, 12: 21–30. |
A, B, C |
Worldwide |
Commentary |
| Krellenstein J, Strub, S: The ethical implications of “treatment as prevention” in the United States. 2012, 16:1–4. |
A, C |
United States |
Commentary |
| Kulkarni SP, Shah KR, Sarma KV, Mahajan AP: Clinical Uncertainties, Health Service Challenges, and Ethical Complexities of HIV “Test-and-Treat”: A Systematic Review.Am J Public Health 2013, 103: e14–e23. |
A, B, C |
Worldwide |
Systematic Review |
| Macklin R, Cowan E: Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention.Health Aff 2012, 31:1537–1544. |
A, B |
United States |
Commentary |
| McNairy ML, Cohen M, El-Sadr WM: Antiretroviral Therapy for Prevention Is a Combination Strategy.Curr HIV/AIDS Rep 2013, 10: 152–8. |
B, C |
Worldwide |
Commentary |
| McNairy ML, Howard AA, El-Sadr WM: Antiretroviral Therapy for Prevention of HIV and Tuberculosis: A Promising Intervention but Not a Panacea.JAIDS 2013, 63: S200–7. |
B, C |
Worldwide |
Commentary |
| Mayer KH: Antiretrovirals for HIV prevention: translating promise into praxis.The Lancet 2011, 378:206–208. |
B, C |
Sub-Saharan Africa |
Commentary |
| Montaner JS: Treatment as prevention: a double hat-trick.The Lancet 2011, 378:208–209. |
C |
Canada |
Commentary |
| Nguyen V-K, Bajos N, Dubois-Arber F, O’Malley J, Pirkle CM: Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention.AIDS 2011, 25:291–293. |
A, C |
Worldwide |
Commentary |
| Ostmann F, Saenz C: Separate Goals, Converging Priorities: On the Ethics of Treatment as Prevention.Developing World Bioethics 2013, 13:57–62. |
A, B |
Worldwide |
Commentary |
| Singh JA: Antiretroviral resource allocation for HIV prevention.AIDS 2013, 27:863–865. |
B, C |
Worldwide |
Commentary |
| Small W, Kerr T: HIV Treatment as Prevention and the Role of Applied Social Science Research.Journal of AIDS & Clinical Research 2013, 02:102e. |
B, C |
Worldwide |
Commentary |
| Cates W: HPTN 052 and the future of HIV treatment and prevention.The Lancet 2011, 378: 224–5. |
A, B, C |
Worldwide |
Correspondence |
|
Lancet Infectious Diseases: Editorial: Treatment as prevention for HIV. The Lancet Infect Dis 2011, 11:651. |
B, C |
Worldwide |
Commentary |
| Vonn M: British Columbia’s ‘seek and treat’ strategy: a cautionary tale on privacy rights and informed consent for HIV testing. HIV/AIDS Policy & Law Review 2012, 16:1–4. |
A, C |
Canada |
Commentary |
| Williams B, Wood R, Dukay V, Delva W, Ginsburg D, Hargrove J, Stander M, Sheneberger R, Montaner J, Welte A: Treatment as prevention: preparing the way. JIAS 2011, 14:S6. | A, B, C | Worldwide | Commentary |
*Only articles that included methods were considered reviews. Articles without methods were considered commentaries.
A = Balancing individual- and population-level interests.
B = Power relations within clinical practice and competing resource demands within health care systems.
C = Effectiveness considerations and socio-structural contexts of HIV-related experience.